急性髓系白血病:2025年诊断、风险分层与管理更新
该综述概述急性髓系白血病(AML)的诊断、风险分层与治疗管理进展。诊断基于血液和/或骨髓中幼稚白血病细胞;欧洲白血病网络发布了基于细胞遗传学和分子学发现的风险分类算法;可测量残留病(MRD)量化能力提高可能改善疗效评估。十二种新获批药物的最佳整合策略仍在讨论中。
要点
- 诊断基于血液和/或骨髓中幼稚白血病细胞的存在。
- 欧洲白血病网络发布了针对强化和非强化治疗患者的风险分类算法。
- 将MRD纳入治疗决策正在快速演变。
核心结论
- 过去十年AML的诊断、风险评估、监测和治疗管理因病理生理理解加深、评估技术进步及至少12种获批疗法的加入而发生显著变化。
- 纳入新药的 optimal 策略仍在讨论中,总体方法整合患者与照护者的治疗目标、合并症和疾病特征。
研究设计与样本
- 综述,检索范围未报告。
主要发现
- AML是一种骨髓干细胞癌症,尽管有可用治疗仍常致命。
- 诊断基于血液和/或骨髓中幼稚白血病细胞的存在,较少见于髓外组织。
- 欧洲白血病网络发布了基于细胞遗传学和分子学发现的、针对强化和非强化治疗患者的风险分类算法。
- 量化更低水平可测量残留病(MRD)的能力提高可能允许更好的疗效评估及疾病状态动态监测。
- 将MRD发现纳入治疗决策正在快速演变。
关键数值与推荐
- 欧洲白血病网络发布了基于细胞遗传学和分子学发现的、针对强化和非强化治疗患者的风险分类算法。
临床怎么用
- 总体方法整合患者与照护者的治疗目标、合并症和疾病特征。
- 将MRD发现纳入治疗决策正在快速演变。
局限性
- 纳入新药的最佳策略仍在讨论中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: Acute myeloid leukemia (AML) is a bone marrow stem cell cancer that is often fatal despite available treatments. Diagnosis, risk assessment, monitoring, and therapeutic management of AML have changed dramatically in the last decade due to increased pathophysiologic understanding, improved assessment technology, and the addition of at least 12 approved therapies. DIAGNOSIS: The diagnosis is based on the presence of immature leukemia cells in the blood, and/or bone marrow or less often in extra-medullary tissues. New biological insights have been integrated into recent classification systems. RISK ASSESSMENT: The European Leukemia Network has published risk classification algorithms for both intensively and non-intensively treated patients based on cytogenetic and on molecular findings. Prognostic factors may differ based on the therapeutic approach. MONITORING: Our increasing ability to quantify lower levels of measurable residual disease (MRD) potentially allows better response assessment, as well as dynamic monitoring of disease status. The incorporation of MRD findings into therapeutic decision-making is rapidly evolving. RISK ADAPTED THERAPY: The availability of 12 newly approved agents has been welcomed; however, optimal strategies incorporating newer agents into therapeutic algorithms are debated. The overarching approach integrates patient and caregiver goals of care, comorbidities, and disease characteristics.
引用
- Shimony S, Stahl M, Stone RM, et al. Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management. Am J Hematol. 2025. PMID: 39936576. doi:10.1002/ajh.27625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。